TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00003524
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Stomach Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT03858621
Drug: fentanyl NOL guided
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery.
Study: NCT03143465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03741257
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: resuscitation fluid
Study: NCT02263976
Drug: BEA 2180 BR
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02263976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02263976
Drug: Methacholine Chloride
Normalized name: Methacholine Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: methacholine challenge test
Study: NCT03938857
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl standard of care
Study: NCT00321620
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
Study: NCT02406586
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salsalate 750 mg
Study: NCT02406586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet
Study: NCT01287962
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po，QD； 28 days every cycle
Study: NCT00962624
Drug: meningococcal B vaccine & meningococcal ACYW conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal B vaccine will be administered at 0, 2 and 6 months and a single dose of meningococcal ACYW vaccine will be administered at 0 months, concomitantly with the first dose of the meningococcal B vaccine.
Study: NCT01384513
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03928184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthcare professional-administered intra-articular injection; performed on Day 1
Study: NCT01815918
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients randomized to treatment arm will three doses of 100 mg of hydrocortisone at the following times: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
Study: NCT01815918
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive placebo prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
Study: NCT00615303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day
Study: NCT00511602
Drug: Technosphere Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technosphere Inhalation Powder
Study: NCT04325490
Drug: Liquid powder
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
Study: NCT01072175
Drug: GSK2118436
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.
Study: NCT01072175
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.
Study: NCT02643420
Drug: SPI-2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
Study: NCT02643420
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard therapy
Study: NCT04154072
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (Sodium Chloride)
Study: NCT02649673
Drug: Pegylated GCSF (PEG-GCSF)
Normalized name: antihemophilic factor (recombinant) pegylated Injection [Adynovate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated GCSF (PEG-GCSF) (e.g. pegfilgrastim) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.
Study: NCT02194335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00682539
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving sham intravitreal injections do not receive an actual injection of study drug. The injecting physician performing the sham injection will be unmasked to the treatment to the treatment assignment regarding active versus sham. The injecting physician will perform the same pre-injection procedures for the patients receiving bevacizumab or triamcinolone, An empty syringe without a needle will be used in the sham injection. The injecting physician will mimic an intraocular injection by making contact with the conjunctiva and applying pressure without the needle. Immediately following the sham injection, the injecting physician will perform the same post-injection procedures as those performed on patients receiving bevacizumab or triamcinolone.
Study: NCT03737812
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for infusion
Study: NCT04470154
Drug: Stage I:HSK21542 0.05 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
Study: NCT04470154
Drug: Stage I:HSK21542 0.15 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
Study: NCT04470154
Drug: Stage I:HSK21542 0.30 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
Study: NCT04470154
Drug: Stage I:HSK21542 0.80 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
Study: NCT04470154
Drug: Stage II:HSK21542 0.3 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
Study: NCT04470154
Drug: Stage II:HSK21542 0.6 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
Study: NCT01418066
Drug: Placebo tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graminis Flores and Maidis stigmata as a powder. Decoction made of 12ml in 100ml hot water. To drink twice daily at least 30 Minutes before a meal.
Study: NCT03165227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally
Study: NCT03854578
Drug: Placebo matching BI 1358894
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT02702076
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of placebo during waking day
Study: NCT00672464
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin will be started at 10 mg at bed time for the first week and 20 mg at bedtime thereafter.
Study: NCT03249259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
Study: NCT00439920
Drug: High-dose anthracycline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00267202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses of placebo were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
Study: NCT00267202
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours.
Study: NCT02778594
Drug: BIA 3-202
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebicapone 50 mg tablets; oral use
Study: NCT02778594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebicapone matching placebo tablets
Study: NCT02778594
Drug: levodopa 100 mg / benserazide 25 mg
Normalized name: levodopa 100 MG / benserazide 25 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use
Study: NCT04499118
Drug: AT regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 Docetaxel 75mg/㎡ d1 1/21d
Study: NCT04499118
Drug: TP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin paclitaxel 125mg/㎡ d1, 8 Cisplatin 75mg/㎡ d1-3 1/21d✖6 or carboplatin AUC6 d1 1/21d✖6
Study: NCT00563056
Drug: Flutiform
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00563056
Drug: Flixotide plus Foradil
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00434317
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03343912
Drug: Estriol 0.400 mg/day and Trimegestone 0.06 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal ring with a nominal delivery rate of 0.400 mg/d estriol (E3) and 0.06 mg/d trimegestone (TMG), vaginal application
Study: NCT03343912
Drug: Estriol 0.300 mg/day and Trimegestone 0.12 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal ring with a nominal delivery rate of 0.300 mg/d estriol (E3) and 0.12 mg/d trimegestone (TMG), vaginal application
Study: NCT03343912
Drug: Estriol 0.200 mg/day and Trimegestone 0.18 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal ring with a nominal delivery rate of 0.200 mg/d estriol (E3) and 0.18 mg/d trimegestone (TMG), vaginal application
Study: NCT01253278
Drug: LY2393910
Approvals — FDA: no, EMA: no, PMDA: no
Description: as capsules, administered orally once daily for two weeks
Study: NCT01253278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: as capsules, administered orally once daily for two weeks
Study: NCT02357654
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00808665
Drug: 0.9% Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
Study: NCT01363232
Drug: BKM120 + MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02967393
Drug: ccIIV4
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00800085
Drug: glucose 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals
Study: NCT01438281
Drug: SYL1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYL1001 eye drops. topical administration
Study: NCT04033926
Drug: KZR-616
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks
Study: NCT04033926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection for 16 weeks
Study: NCT00746681
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, Oral, twice daily for 4 weeks
Study: NCT01578447
Drug: DepoSubQ Provera 104 in Uniject
Approvals — FDA: no, EMA: no, PMDA: no
Description: DepoSubQ Provera 104 in Uniject
Study: NCT03910634
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks
Study: NCT04098003
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rosuvastatin 20 mg daily or placebo for eight weeks
Study: NCT04098003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo control
Study: NCT03448406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT01473108
Drug: Eplerenone (Inspra®)
Normalized name: eplerenone Oral Tablet [Inspra]
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of 50 mg eplerenone
Study: NCT01473108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step
Study: NCT04197245
Drug: saline injection therapy in post-acne atrophic scars
Normalized name: Scar Zone A Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline injection contains 0.9% isotonic sodium chloride solution
Study: NCT01670084
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01670084
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01670084
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or IT
Study: NCT01670084
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01424384
Drug: GSK424887
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurophysiological testing
Study: NCT01424384
Drug: Plactebo To Match
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurophysiological testing
Study: NCT02101866
Drug: Vapendavir 300 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet - single dose
Study: NCT02101866
Drug: Vapendavir 132 mg capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules - single dose
Study: NCT05104138
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients underwent eplerenone treatment for 6 months
Study: NCT01713920
Drug: SEVIKAR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01081002
Drug: Diluted gentian root solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: As a basis, an infusion of water (45%), ethanol (35%) and gentian root cut will be used. The gentian root infusion is approved as a natural flavor in the food industry.3 min before the endoscopy under propofol sedation 4 puffs of this gentian root infusion will be sprayed on the pharynx as a pharyngeal anesthesia
Study: NCT00287261
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg IV every 3 weeks for 36 weeks
Study: NCT04606225
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of placebo (oral)
Study: NCT00658918
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00212108
Drug: celecoxib, gefitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of ZD1839 to be administered is 250mg. ZD1839 will be taken once daily in the morning at approximately the same time each day. If the patient inadvertently did not take the dose in the morning, the patient may take that dose anytime up to 10pm that same day. The daily treatment will be resumed the next day at the scheduled morning dose. Celecoxib will be administered at 400 mg bd.
Study: NCT02866786
Drug: ethinyl estradiol and cyproterone acetate
Normalized name: cyproterone / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptive Pill
Study: NCT02307825
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The drug will be taken three times a week for four months.
Study: NCT02307825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be taken three times a week for four months.
Study: NCT04502095
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02592980
Drug: Traditional anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The physician will adjust the dose according to current INR value based on guidelines.
Study: NCT01377194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
Study: NCT03204331
Drug: Estradiol/norethindrone acetate
Normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
Study: NCT03204331
Drug: Estradiol/norethindrone acetate placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
Study: NCT00529594
Drug: placebo (Control Group)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
Study: NCT00529594
Drug: Etoricoxib (Treatment Group)
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
Study: NCT03772249
Drug: Placebo for DCR-HBVS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile 9% saline for injection.
Study: NCT03234595
Drug: Cerebraca wafer
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will receive Cerebraca wafer implantation with adjuvant temozolomide (TMZ) for the safety and efficacy in this study. At Phase I, the MTD will be determined by DLT. At Phase IIa, up to 12 evaluable patients will be enrolled for the efficacy and safety of Cerebraca wafer implantation. At Phase IIa, the cavity surface after tumor removal will be maximally covered by Cerebraca wafer without exceeding the MTD defined at Phase I. Patients in Phase I receive treatment as designed for Phase IIa, the data will be incorporated into Phase IIa to reduce the patient number. The overall patient number in this study is therefore between 2 to 36 evaluable patients.
Study: NCT02623972
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered IV with adriamycin for 4 cycles
Study: NCT01108588
Drug: Placebo (to match Aspirin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo grossly matched Aspirin 300 mg daily
Study: NCT01108588
Drug: Comparator: Placebo (to match Clopidogrel)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (grossly matched Clopidogrel 75 mg) daily
Study: NCT00422227
Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO~* Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO~* Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day~* Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily
Study: NCT03418727
Drug: Corticosteroid Eye Drop
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drop to be administered after Brimonidine in treatment arm 1
Study: NCT01207427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01207427
Drug: ADL5945 0.1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01207427
Drug: ADL5945 0.25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02380573
Drug: FD&C Blue # 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01375491
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: generic doxycycline 100mg twice daily
Study: NCT03755713
Drug: ASP0892
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal
Study: NCT03755713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal; normal saline solution
Study: NCT01231906
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01231906
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00020488
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00020488
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00020488
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes